covid‐19, нарушение свертываемости крови, коагулопатия, двс-синдром, антикоагулянтная терапия, профилактика, Medicine

COVID-19 leads to a cytokine storm, a systemic inflammatory response, and coagulopathy, which is one of the worst prognostic factors. Coagulopathy in COVID-19 is accompanied by a pronounced increase in D-dimer and fibrin/fibrinogen breakdown products, while deviations in other parameters (prothrombin time, activated partial thromboplastin time, platelet count) at the onset of the disease are relatively rare. For coagulopathy associated with COVID-19, empiric anticoagulant therapy aimed at preventing venous thrombosis and thromboembolism, as well as standard maintenance therapy for sepsis-induced coagulopathy or disseminated intravascular coagulation syndrome, should be carried out.